Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
58 hedge funds and large institutions have $157M invested in Unity Biotechnology in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 10 closing their positions.
1,800% more call options, than puts
Call options by funds: $76K | Put options by funds: $4K
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
18% more capital invested
Capital invested by funds: $133M → $157M (+$24.5M)
2% more funds holding
Funds holding: 57 → 58 (+1)
0.04% more ownership
Funds ownership: 3.82% → 3.86% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.66M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.33M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.17M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$878K |
| 5 |
SCM
Sio Capital Management
New York
|
+$856K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.86M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.07M |
| 4 |
Millennium Management
New York
|
-$491K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$280K |
UBX Hedge Fund Activity: Q2 2019 in Review
58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2019, worth a combined $157M — up 18% from $133M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new UBX positions and 10 closed out — a net gain of 4 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.66M. The largest seller was Morgan Stanley, cutting an estimated $2.86M.
- 58 institutional investors held Unity Biotechnology (UBX) as of Q2 2019, up from 57 in Q1 2019.
- Funds reported $157M of Unity Biotechnology stock for Q2 2019, up 18% quarter-over-quarter.
- 14 funds opened new Unity Biotechnology positions in Q2 2019 and 10 closed out, a net change of +4 holders.
- The largest Unity Biotechnology buyer in Q2 2019 was Citadel Advisors, an estimated $1.66M added.
- The largest Unity Biotechnology seller in Q2 2019 was Morgan Stanley, an estimated $2.86M sold.
Based on aggregated 13F filings for Q2 2019.